Literature DB >> 2341111

The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.

C Salvadori1, C Ward, R Defrance, R Hopkins.   

Abstract

A balanced 3 way cross-over study involving 12 young healthy volunteers (6 men and 6 women) was used to determine the pharmacokinetic parameters of the antidepressant tianeptine following a single dose administered by oral and intravenous route. The influence of alcohol on the pharmacokinetics of tianeptine when given per os was also investigated. Kinetic parameters of metabolite MC5, the C5 side chain beta-oxidation product of tianeptine, were simultaneously determined. Following intravenous administration total clearance and volume of distribution of tianeptine were 230 +/- 59 ml.min-1 and 0.47 +/- 0.14 l.kg-1 respectively. When given orally, tianeptine was absorbed rapidly (tmax = 0.94 +/- 0.47 h). The mean systemic availability was estimated to be 99 +/- 29%. Tianeptine was eliminated from plasma with a half-life of 2.5 +/- 1.1 h, mainly via extrarenal route since its renal clearance averaged 0.38 +/- 0.47 ml.min-1. Plasma levels of metabolite MC5 were lower than those of the parent drug but decreased with a longer half-life (7.2 +/- 5.7 h). Alcohol co-administration decreased tianeptine absorption rate and lowered tianeptine plasma levels by about 30% but did not affect those of the MC5 metabolite.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341111     DOI: 10.1111/j.1472-8206.1990.tb01021.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

Review 1.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; G Zyhlarz
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Alcohol-induced depressive-like behavior is associated with cortical norepinephrine reduction.

Authors:  Bruk Getachew; Sheketha R Hauser; Robert E Taylor; Yousef Tizabi
Journal:  Pharmacol Biochem Behav       Date:  2010-06-30       Impact factor: 3.533

4.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Development of a population pharmacokinetic database for tianeptine.

Authors:  T H Grasela; J B Fiedler-Kelly; C Salvadori; C Marey; R Jochemsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 7.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.

Authors:  M I Wilde; P Benfield
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

8.  Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine.

Authors:  Robert H Wichers; James L Findon; Auke Jelsma; Vincent Giampietro; Vladimira Stoencheva; Dene M Robertson; Clodagh M Murphy; Sarah Blainey; Grainne McAlonan; Christine Ecker; Katya Rubia; Declan G M Murphy; Eileen M Daly
Journal:  Mol Autism       Date:  2021-02-19       Impact factor: 7.509

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.